A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration

NCT02555306 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Age-Related Macular Degeneration

Interventions

DRUG: 0.5 mg of DE-122
DRUG: 1.0 mg of DE-122
DRUG: 2.0 mg of DE-122
DRUG: 4.0 mg of DE-122

Sponsor

Santen Inc.